Literature DB >> 24473440

Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B.

Mattijs M Heemskerk1, Sjoerd A A van den Berg, Amanda C M Pronk, Jan-Bert van Klinken, Mariëtte R Boon, Louis M Havekes, Patrick C N Rensen, Ko Willems van Dijk, Vanessa van Harmelen.   

Abstract

The lipid-lowering effect of niacin has been attributed to the inhibition of cAMP production in adipocytes, thereby inhibiting intracellular lipolysis and release of nonesterified fatty acids (NEFA) to the circulation. However, long-term niacin treatment leads to a normalization of plasma NEFA levels and induces insulin resistance, for which the underlying mechanisms are poorly understood. The current study addressed the effects of long-term niacin treatment on insulin-mediated inhibition of adipocyte lipolysis and focused on the regulation of cAMP levels. APOE*3-Leiden.CETP transgenic mice treated with niacin for 15 wk were subjected to an insulin tolerance test and showed whole body insulin resistance. Similarly, adipocytes isolated from niacin-treated mice were insulin resistant and, interestingly, exhibited an increased response to cAMP stimulation by 8Br-cAMP, β1- and β2-adrenergic stimulation. Gene expression analysis of the insulin and β-adrenergic pathways in adipose tissue indicated that all genes were downregulated, including the gene encoding the cAMP-degrading enzyme phosphodiesterase 3B (PDE3B). In line with this, we showed that insulin induced a lower PDE3B response in adipocytes isolated from niacin-treated mice. Inhibiting PDE3B with cilostazol increased lipolytic responsiveness to cAMP stimulation in adipocytes. These data show that long-term niacin treatment leads to a downregulation of PDE3B in adipocytes, which could explain part of the observed insulin resistance and the increased responsiveness to cAMP stimulation.

Entities:  

Keywords:  adenosine 3′,5′-cyclic monophosphate; adipose tissue; lipolysis; phosphodiesterases

Mesh:

Substances:

Year:  2014        PMID: 24473440      PMCID: PMC3962609          DOI: 10.1152/ajpendo.00641.2013

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  27 in total

1.  Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.

Authors:  Marit Westerterp; Caroline C van der Hoogt; Willeke de Haan; Erik H Offerman; Geesje M Dallinga-Thie; J Wouter Jukema; Louis M Havekes; Patrick C N Rensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-08-31       Impact factor: 8.311

2.  Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP.

Authors:  H Liu; D H Maurice
Journal:  Br J Pharmacol       Date:  1998-12       Impact factor: 8.739

Review 3.  Inhibition of the mobilization of free fatty acids from adipose tissue. Physiological aspects on the mechanisms for the inhibition of mobilization of FFA from adipose tissue.

Authors:  L A Carlson
Journal:  Ann N Y Acad Sci       Date:  1965-10-08       Impact factor: 5.691

Review 4.  Niacin: vitamin and antidyslipidemic drug.

Authors:  Elaine L Jacobson; H Kim; M Kim; M K Jacobson
Journal:  Subcell Biochem       Date:  2012

5.  Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production.

Authors:  W Wang; A Basinger; R A Neese; B Shane; S A Myong; M Christiansen; M K Hellerstein
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-03       Impact factor: 4.310

6.  Molecular identification of nicotinic acid receptor.

Authors:  Takatoshi Soga; Masazumi Kamohara; Jun Takasaki; Shun-ichiro Matsumoto; Tetsu Saito; Takahide Ohishi; Hideki Hiyama; Ayako Matsuo; Hitoshi Matsushime; Kiyoshi Furuichi
Journal:  Biochem Biophys Res Commun       Date:  2003-03-28       Impact factor: 3.575

7.  Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.

Authors:  José W A van der Hoorn; Willeke de Haan; Jimmy F P Berbée; Louis M Havekes; J Wouter Jukema; Patrick C N Rensen; Hans M G Princen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-31       Impact factor: 8.311

8.  Effects of reduced free fatty acid availability on hormone-sensitive lipase activity in human skeletal muscle during aerobic exercise.

Authors:  Marcus O'Neill; Matthew J Watt; George J F Heigenhauser; Lawrence L Spriet
Journal:  J Appl Physiol (1985)       Date:  2004-06-18

9.  Reduced plasma FFA availability increases net triacylglycerol degradation, but not GPAT or HSL activity, in human skeletal muscle.

Authors:  Matthew J Watt; Anna G Holmes; Gregory R Steinberg; Jose L Mesa; Bruce E Kemp; Mark A Febbraio
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-01-28       Impact factor: 4.310

10.  PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect.

Authors:  Sorin Tunaru; Jukka Kero; Annette Schaub; Christian Wufka; Andree Blaukat; Klaus Pfeffer; Stefan Offermanns
Journal:  Nat Med       Date:  2003-02-03       Impact factor: 53.440

View more
  9 in total

1.  Vitamins and non-alcoholic fatty liver disease: A Molecular Insight.

Authors:  Sana Raza; Archana Tewari; Sangam Rajak; Rohit A Sinha
Journal:  Liver Res       Date:  2021-04-04

2.  Nutrient Restriction Increases Circulating and Hepatic Ceramide in Dairy Cows Displaying Impaired Insulin Tolerance.

Authors:  Amanda N Davis; J L Clegg; C A Perry; J W McFadden
Journal:  Lipids       Date:  2017-08-23       Impact factor: 1.880

3.  Dosing profile profoundly influences nicotinic acid's ability to improve metabolic control in rats.

Authors:  Tobias Kroon; Ann Kjellstedt; Pia Thalén; Johan Gabrielsson; Nicholas D Oakes
Journal:  J Lipid Res       Date:  2015-07-13       Impact factor: 5.922

4.  Prolonged niacin treatment leads to increased adipose tissue PUFA synthesis and anti-inflammatory lipid and oxylipin plasma profile.

Authors:  Mattijs M Heemskerk; Harish K Dharuri; Sjoerd A A van den Berg; Hulda S Jónasdóttir; Dick-Paul Kloos; Martin Giera; Ko Willems van Dijk; Vanessa van Harmelen
Journal:  J Lipid Res       Date:  2014-10-15       Impact factor: 5.922

5.  Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments.

Authors:  Robert Andersson; Tobias Kroon; Joachim Almquist; Mats Jirstrand; Nicholas D Oakes; Neil D Evans; Michael J Chappel; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-21       Impact factor: 2.745

Review 6.  Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue.

Authors:  Sofia Dias; Sílvia Paredes; Laura Ribeiro
Journal:  Int J Endocrinol       Date:  2018-01-17       Impact factor: 3.257

Review 7.  NAD+ and its possible role in gut microbiota: Insights on the mechanisms by which gut microbes influence host metabolism.

Authors:  Zhongxiang Ren; Yetong Xu; Tiejun Li; Weizhong Sun; Zhiru Tang; Yongsheng Wang; Kaifeng Zhou; Jigang Li; Qi Ding; Kaiyang Liang; Liuting Wu; Yulong Yin; Zhihong Sun
Journal:  Anim Nutr       Date:  2022-06-22

8.  The TBK1/IKKε inhibitor amlexanox improves dyslipidemia and prevents atherosclerosis.

Authors:  Peng Zhao; Xiaoli Sun; Zhongji Liao; Hong Yu; Dan Li; Zeyang Shen; Christopher K Glass; Joseph L Witztum; Alan R Saltiel
Journal:  JCI Insight       Date:  2022-09-08

Review 9.  The Role of Vitamins in the Pathogenesis of Non-alcoholic Fatty Liver Disease.

Authors:  Jiawei Li; Paul Cordero; Vi Nguyen; Jude A Oben
Journal:  Integr Med Insights       Date:  2016-04-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.